Special Issue

Functional Nanohybrids for Drug Delivery

Message from the Guest Editors

Nanomaterial-based drug delivery systems have been seen as a publicly-known strategy to improve therapeutic efficacy in cancer therapies. However, dense extracellular matrix and interstitial fluid pressure in the tumor suppress deep delivery and lead to inhomogeneous treatments. Not only able to accumulate at highly permeable peripheral blood vessels via enhanced permeability and retention effects. nanohybrids should also be concerned with different functions to enhance drug delivery. Stimuli-response and functions of nanohybrids are two impressive manipulations. In addition, targeting moiety for specific diseases also shelters the mononuclear phagocyte system and promotes drug delivery. Therefore, blood circulation obstacles, tumor accumulation, and penetrated delivery should be comprehensively considered, thus multifunctional nanohybrids will be the ideal platforms for enhanced drug delivery. The development of new nanohybrids is an important step of drug delivery systems.

This Special Issue aims of highlighting current progress in multifunctional nanohybrids for enhanced drug delivery.

Guest Editors

Dr. Shang-Hsiu Hu

Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300044, Taiwan

Dr. Chien-Wen Chang

Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan

Deadline for manuscript submissions

closed (30 January 2019)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/12300

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

